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ABSTRACT
Objectives A recent study identified 16 genetic
variants associated with N-glycosylation of human IgG.
Several of the genomic regions where these single
nucleotide polymorphisms (SNPs) reside have also been
associated with autoimmune disease (AID) susceptibility,
suggesting there may be pleiotropy (genetic sharing)
between loci controlling both N-glycosylation and AIDs.
We investigated this by testing variants associated with
levels of IgG N-glycosylation for association with
rheumatoid arthritis (RA) susceptibility using a
Mendelian randomisation study, and testing a subset of
these variants in a less well-powered study of treatment
response and severity.
Methods SNPs showing association with IgG
N-glycosylation were analysed for association with RA
susceptibility in 14 361 RA cases and 43 923 controls.
Five SNPs were tested for association with response to
anti-tumour necrosis factor (TNF) therapy in 1081 RA
patient samples and for association with radiological
disease severity in 342 patients.
Results Only one SNP (rs9296009) associated with
N-glycosylation showed an association (p=6.92×10–266)
with RA susceptibility, although this was due to linkage
disequilibrium with causal human leukocyte antigen
(HLA) variants. Four regions of the genome harboured
SNPs associated with both traits (shared loci); although
statistical analysis indicated that the associations
observed for the two traits are independent. No SNPs
showed association with response to anti-TNF therapy.
One SNP rs12342831 was modestly associated with
Larsen score (p=0.05).
Conclusions In a large, well-powered cohort of RA
patients, we show SNPs driving levels of N-glycosylation
have no association with RA susceptibility, indicating
colocalisation of associated SNPs are not necessarily
indicative of a shared genetic background or a role for
glycosylation in disease susceptibility.
INTRODUCTION
Glycosylation, a post-translational protein modifica-
tion in which a carbohydrate is attached to a
hydroxyl group, was first implicated in rheumatoid
arthritis (RA) when serum IgG glycosylation was
associated with the disease.1 IgG antibodies have
one conserved N-glycosylation site in the Fc
portion of their heavy chains, shown to influence
the structure and effector functions of IgG anti-
bodies where distinct patterns of glycosylation on
anticitrullinated protein antibodies have been
detected prior to the onset of RA.2 In addition, a lack
of total IgG Fc galactosylation has been shown to cor-
relate with RA disease activity and severity, with
levels of N-terminal glycosylation being restored by
treatment with anti-tumour necrosis factor (TNF)
drugs.3 Therefore, there is accumulating evidence
and interest in the hypothesis that glycosylation plays
a role in susceptibility and outcome in RA.
A recent genome-wide association analysis identi-
fied 10 confirmed loci (p<2.27×10−9) and 7
strongly suggestive loci (p<5×10−8) associated
with N-glycosylation of human IgG.4 Several of the
loci identified have previously been associated with
autoimmune diseases (AIDs); therefore, it has been
suggested that there may be pleiotropy (shared
genetic contribution) between loci controlling
N-glycosylation and loci controlling AIDs.
To investigate this theory, we have performed a
Mendelian randomisation study, testing variants pre-
viously associated with levels of IgG N-glycosylation
for association with RA susceptibility. We also tested
a subset of these single nucleotide polymorphisms
(SNPs) in a smaller cohort for any indication that
they may be involved in treatment response or sever-
ity in RA. Association of the same variants that
control IgG N-glycosylation with susceptibility to or
outcome of RAwould provide an unbiased confirm-
ation of the hypothesis that N-glycosylation is
important in RA.5
METHODS
Susceptibility analysis
The samples and data analysis, described previ-
ously,6 were from 18 studies with a total of 14 361
RA cases and 43 923 controls of European ancestry.
This provided 98% power to detect an OR=1.10
at the 0.05 significance level (α), for a SNP with
minor allele frequency (MAF)=20%. SNPs
showing evidence of association with IgG
N-glycosylation4 were analysed for association with
RA (table 1). Of the 17 SNPs, 16 were selected for
analysis, while no data were available for 1 SNP
(rs1049110) in the human leukocyte antigen
(HLA) region. Association analysis consisted of
logistic regression correcting for up to 10 principal
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Table 1 Meta-analysis results, testing SNPs associated with glycosylation for association with RA
Chr SNP
SNP
position Locus Allele 1 Allele 2
Number of studies
in meta-analysis
Number
of cases
Number
of controls
Frequency
of allele 1
Beta
coefficient SE p Value
3 Rs11710456 186725887 ST6GAL1 A G 11 8875 29 367 0.28 0.017 0.02 0.44
3 Rs7652995 186722944 ST6GAL1 A G 11 8875 29 367 0.84 0.028 0.02 0.29
5 Rs17348299 55322895 IL6ST-ANKRD55 A C 11 8875 29 367 0.16 −0.006 0.03 0.84
7 Rs6421315 50355207 IKZF1 G C 18 14 361 43 923 0.61 0.05 0.01 0.003
7 Rs1122979 150915071 ABCF2-SMARCD3 A G 11 8875 29 367 0.12 −0.04 0.0305 0.20
9 Rs12342831 33124872 B4GALT1 T C 17 13 964 43 524 0.74 −0.03 0.02 0.07
11 Rs4930561 67931761 SUV420H1 A G 11 8875 29 367 0.49 0.04 0.02 0.03
14 Rs11847263 65775695 FUT8 T G 11 8875 29 367 0.66 −0.006 0.02 0.77
22 Rs2186369 24170996 SMARCB1-DERL3 T G 11 8875 29 367 0.84 0.04 0.03 0.18
22 Rs909674 39859169 SYNGR1-TAB1-MGAT3-CACNA1 A C 18 14 361 43 923 0.73 −0.02 0.02 0.23
6 Rs9296009 32114515 PRRT1 A T 18 14 361 43 923 0.79 −0.61 0.02 6.92×10−266
6 Rs1049110 32726803 HLA-DQA2, HLA-DQB2 SNP not in data
6 Rs404256 90657783 BACH2 T C 18 14 361 43 923 0.42 0.003 0.02 0.85
7 Rs2072209 107592198 LAMB1 A G 17 12 841 33 416 0.93 0.03 0.03 0.35
9 Rs4878639 36099399 RECK T C 11 8875 29 367 0.72 −0.002 0.02 0.93
12 Rs12828421 7335217 PEX5 T C 10 7355 18 860 0.48 0.004 0.02 0.84
17 Rs7224668 79235788 SLC38A10 T C 11 8875 29 367 0.45 −0.02 0.02 0.24
Loci shown in bold italics have previously been associated with RA (different SNP). The LD between the glycosylation SNP and RA SNP in these regions are shown in table 2. SNP p values in the individual studies included in the meta-analysis can be found
in online supplementary table S1.
Chr, chromosome; LD, linkage disequilibrium; RA, rheumatoid arthritis.
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components. A genome-wide association study meta-analysis
was then performed using an inverse variance method assuming
a fixed effects model on the effect estimates (β).
Treatment response analysis
Genotype data were available for five of the SNPs associated with
glycosylation in 1039 RA patient samples from the Biologics in
Rheumatoid Arthritis Genetics and Genomics Study Syndicate
(BRAGGSS).7 Multivariate linear regression was carried out to
test the association of each SNP with response to anti-TNF treat-
ment, measured as either absolute change in DAS28 from base-
line to 6 months,8 or according to the 6-month response criteria
defined by European League Against Rheumatism (EULAR).9 All
regression analyses were adjusted for covariates known to be pre-
dictors of response in this cohort; baseline DAS28, baseline
Health Assessment Questionnaire score, concurrent disease-
modifying anti-rheumatic drug therapy and gender, as described
previously.10 As patients in the cohort received different
anti-TNF drugs, a stratified analysis was also carried out.
Outcome/severity analysis
Lack of total IgG Fc galactosylation has been shown to correlate
with RA disease activity and severity. Data were available for five
SNPs in patient samples from the Norfolk Arthritis Register, a
primary care-based inception cohort of patients with recent
onset inflammatory polyarthritis.11 These were tested for associ-
ation with disease severity defined as radiographic damage mea-
sured by Larsen score and erosions. A generalised linear
regression model was used to analyse SNP associations with ero-
sions as a binary variable, using generalised estimating equations
(STATAs xtgee). The analysis incorporated time points up to
5 years of follow-up for all patients, and was performed for
disease duration <7.5 years. Generalised linear latent and mixed
modelling was used to test the association of SNPs associated
with glycosylation for association with Larsen score. To account
for change in the tested variable (eg, Larsen score) over time,
disease duration was included in all models, along with the
linear quadratic terms of disease duration to account for non-
linear changes over time. The same was done for age at onset as
described previously.12
RESULTS
Of the 16 SNPs previously associated with glycosylation only
one SNP (rs9296009) showed association with RA
(p=6.92×10−266); however, this SNP lies within the HLA
region which confers the largest genetic association with RA.
The glycosylation SNP is in modest linkage disequilibrium (LD)
with the most associated variants in this region (rs660895/
rs6910071 (both tag HLA-DRB1*0401) r2=0.29, D0=0.55) and
the effect observed at the glycosylation SNP is not independent
of the HLA-DRB1 susceptibility SNPs.
The HLA association with RA can be almost completely
explained by five amino acid positions, three in HLA-DRB1,
position 9 at HLA-B and HLA-DPB1.13 Conditioning on these
five amino acids showed no evidence of a residual association in
the region. Therefore, the glycosylation SNP, rs9296009, is not
the lead, causal SNP in the region and there is no evidence it is
independently associated with RA susceptibility.
One other SNP (rs6421315), within the IKZF1 gene, showed
modest association with RA (p=0.003). For four non-HLA loci,
which contain both a SNP associated with glycosylation and a
SNP associated with RA susceptibility, we examined the extent
to which these associations are likely to arise from a shared
genetic signal by assessing the extent of LD between the glycosy-
lation associated SNPs and the RA associated SNPs (table 2). No
evidence of significant LD was found between the SNPs in an
independent dataset of 4861 European samples with genotypes
available at >55 000 SNPs, suggesting that the associations
observed for the two traits at these loci are independent.
Further, no evidence of association was detected to the 340
SNPs from the 17 loci that showed evidence of association to a
range of glycosylation traits.
We also found no evidence association with any of the five
glycosylation SNPs tested with treatment response measured by
change in DAS28 or EULAR response (see online
supplementary tables S1 and S2).
Stratified analysis showed a modest association between
rs9296009 in the PRRT1 locus (p=0.02) and response to eta-
nercept (n=346) measured by change in DAS28, but not when
response was measured by EULAR criteria. A modest association
was also seen with a SNP in the HLA-DRB1 region (rs9268839)
and response to infliximab when measured by change in DAS28
(p=0.035) (n=322) and EULAR response criteria (p=0.002)
(n=330) (see online supplementary tables S1 and S2).
One SNP, rs12342831, was modestly associated with severity
in patients meeting American College of Rheumatology (ACR)
criteria cumulatively after 5 years (n=221) (p=0.054) (see
online supplementary table S3).
DISCUSSION
In a large, well-powered cohort of RA patients, a Mendelian
randomisation approach showed no evidence to support the
hypothesis that SNPs associated with N-glycosylation of IgG are
associated with susceptibility to RA.
One SNP in the IKZF1 locus showed modest association with
RA in the meta-analysis (p=0.003), although it did not remain
significant after correcting for multiple testing for 16 SNPs
(Bonferroni corrected p value 0.05). Interestingly, IKZF1 knock-
out mice were shown to have different expression of IgG
Table 2 Linkage disequilibrium between SNPs associated with glycosylation and SNPs in the same loci previously associated with RA
Chr SNPs associated with glycosylation (9) Locus SNP associated with RA (reference) r2 D0
5 Rs17348299 IL6ST-ANKRD55 rs71624119 0.003 0.214
rs7731626 0.002 0.149
Rs6859219 0.001 0.167
9 Rs12342831 B4GALT1 rs11574914 (RA locus named CCL19-CCL21) 0 0.011
22 Rs909674 SYNGR1-TAB1-MGAT3-CACNA1 rs909685 (RA locus named SYNGR1) 0.108 0.848
6 Rs404256 BACH2 rs72928038 0 0.023
Linkage disequilibrium was calculated in an independent dataset of 4861 European samples where data was available for >55 000 SNPs.
Chr, chromosome; RA, rheumatoid arthritis.
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N-glycans when compared with wild type.4 Further, different
IgG N-glycan profiles exist in patients with systemic lupus ery-
thematosus (SLE) when compared with controls, making this
locus an intriguing target for further investigation. Although
this locus shows no evidence for association with RA, it is asso-
ciated with SLE and other AID including type 1 diabetes
(T1D).14 15 However, there is only very low LD between the
glycosylation SNP (rs6421315) and the lead SLE or T1D var-
iants respectively (rs2366293 r2=0.04 D0=0.6, rs10272724
r2=0.001, D0=0.032) suggesting possible independence.
A previous study of 127 female RA patients, followed for
6 years, showed that patients with a higher percentage of agalac-
tosyl IgG oligosaccharides G(O) in serum had significantly more
erosions and disease activity than patients with lower levels.3
Therefore, we tested the association of glycosylation SNPs with
both response to anti-TNF therapy and disease severity in RA
patients but found no evidence to support the theory that glyco-
sylation SNPs predict outcome. Although larger than the previ-
ous study, it should be noted that the severity analysis remained
underpowered, and is a major limitation of the analysis. Hence,
results should be interpreted with caution and it is recom-
mended that investigation of the effect of these glycosylation
SNPs on disease outcome should be repeated in a larger cohort.
Information on glycosylation was not available in our cohort,
and therefore, we could not directly test the association of var-
iants with glycosylation. However, the use of Mendelian ran-
domisation in the largest sample size to date has demonstrated
that SNPs associated with glycosylation are not the same as
those associated with RA as previously suggested, highlighting
that care should be taken when inferring causality. This does
not mean that glycosylation is not involved in RA; it could be a
biomarker of RA as it has been shown to appear several years
before disease onset.
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